II. Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-75. (Cancelled)

Okay to enter
JSL
9-22-2003

76. (Currently amended) An ApoA-I agonist compound comprising:

(i) an 18 to 22-residue peptide or peptide analogue which forms an amphipathic α-helix in the presence of lipids and which comprises formula (I):

Z_1-X_1-X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9-X_{10}-X_{11}-X_{12}-X_{13}-X_{14}-X_{15}-X_{16}-X_{17}-X_{18}-Z_2

or a pharmaceutically acceptable salt thereof, wherein

X_1 is Pro (P), Ala (A), Gly (G), Asn (N), Gln (Q) or D-pro (p);

X_2 is an aliphatic residue;

X_3 is Leu (L);

X_4 is an acidic residue;

X_5 is Leu (L) or Phe (F);

X_6 is Leu (L) or Phe (F);

X_7 is a basic residue;

X_8 is an acidic residue;

X_9 is Leu (L) or Trp (W);

X_{10} is Leu (L) or Trp (W);

X_{11} is an acidic residue or Asn (N);

X_{12} is an acidic residue;

X_{13} is Leu (L), Trp (W) or Phe (F);

X_{14} is a basic residue or Leu (L);

X_{15} is Gln (Q) or Asn (N);

X_{16} is a basic residue;

X_{17} is Leu (L);

X_{18} is a basic residue;

wherein at least one L-enantiomeric residue of [the peptide or peptide analogue] formula (I) is [[a]] replaced with an identical D-enantiomeric residue;